论文部分内容阅读
目的探讨血清β2-微球蛋白(β2-MG)对食道癌、肝癌及肠癌辅助诊断的价值。方法选择2009年10月-2011年5月我院食道癌、肝癌及肠癌患者226例(肿瘤组),正常体检人群200例作为对照(对照组)。用化学发光法测定正常人群、肿瘤患者血清β2-MG,并对其结果进行统计学处理。结果肿瘤组β2-MG的含量高于对照组[(4513.2±619.8)ng/ml vs.(1668.3±88.9)ng/ml,P<0.05];两组人群中,年龄51-80岁血清中β2-MG含量高于年龄30-50岁者(P<0.05)。食道癌、肝癌、肠癌三种不同肿瘤患者中,肝癌β2-MG阳性检出率最高,血清β2-MG含量最高。结论血清β2-MG含量在食道癌、肝癌、肠癌患者中增高,对其相关肿瘤的辅助诊断有一定的临床意义。
Objective To investigate the value of serum β2-microglobulin (β2-MG) in the diagnosis of esophageal cancer, liver cancer and colorectal cancer. Methods Totally 226 patients (tumor group) with esophageal cancer, liver cancer and colorectal cancer in our hospital from October 2009 to May 2011 were selected as the control group. Chemiluminescence method was used to detect the serum β2-MG in normal population and tumor patients, and the results were statistically analyzed. Results The level of β2-MG in the tumor group was significantly higher than that in the control group [(4513.2 ± 619.8) ng / ml vs. (1668.3 ± 88.9) ng / ml, P <0.05] -MG content was higher than those of 30-50 years old (P <0.05). Esophageal cancer, liver cancer, intestinal cancer in three different cancer patients, liver cancer β2-MG positive detection rate, serum β2-MG content was the highest. Conclusion Serum β2-MG levels are increased in patients with esophageal cancer, liver cancer and colorectal cancer, and have certain clinical significance for the diagnosis of related tumors.